SCHEMBL4517295

SCHEMBL4517295

CCOC(=O)/C=C/c1ccc([Se]c2ccc3c(c2)C(C)(C)CC=C3c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 5/20 0.41
RARA P10276 4/20 0.41
RARG P13631 4/20 0.41
RXRA P19793 1/20 0.38
NR2E1 Q9Y466 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CYP3A4 P08684 1/20 0.37
TTR P02766 1/20 0.36
DPP4 P27487 1/20 0.36
FDPS P14324 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
MAOB P27338 1/20 0.34
CYP1A2 P05177 1/20 0.34
ESR1 P03372 1/20 0.33
ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4517299 1.00 RARB (0.41) RARBRARARARGRXRANR2E1
SCHEMBL4516961 0.93 RARA (0.39) RARBRARARARGRXRANR2E1
SCHEMBL4516963 0.93 RARA (0.39) RARBRARARARGRXRANR2E1
SCHEMBL4497873 0.91 RARB (0.41) RARBRARARARGRXRANR2E1
SCHEMBL4500556 0.88 RARB (0.46) RARBRARARARGRXRANR2E1
SCHEMBL4500557 0.88 RARB (0.46) RARBRARARARGRXRANR2E1
SCHEMBL4509109 0.84 RARB (0.39) RARBRARARARGRXRANR2E1
SCHEMBL4506863 0.80 RARB (0.48) RARBRARARARGRXRANR2E1
SCHEMBL4500268 0.80 RARB (0.44) RARBRARARARGRXRANR2E1
SCHEMBL4500264 0.80 RARB (0.44) RARBRARARARGRXRANR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592478-B2 Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-09-22 US disclosed
US-20080213347-A1 Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. 2008-09-04 US disclosed
EP-1565433-B1 NOVEL LIGANDS THAT ARE ANTAGONISTS OF RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2007-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213347-A1 Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof RARB, RARG, RARA RARB 1/4885RARA 3/4885RARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.